Description
Carboplatin Medak (Carboplatin) Concentrate for Infusions 10 mg/ml. 5 ml. Vial №1
Composition
The main active ingredient in Carboplatin Medak is Carboplatin, a platinum-containing compound with a molecular formula of C6H12N2O4Pt.
Mechanism of Action
Carboplatin, a platinum coordination complex, exerts its cytotoxic effect by forming DNA cross-links, thereby inhibiting DNA replication and transcription in rapidly dividing cancer cells.
Pharmacological Properties
Carboplatin Medak is a cytotoxic agent that interferes with DNA repair mechanisms and induces apoptosis in cancer cells. It exhibits dose-dependent antitumor activity.
Indications for Use
Carboplatin Medak is indicated for the treatment of advanced ovarian carcinoma of epithelial origin. It may also be used for other types of cancer as determined by the prescribing healthcare provider based on individual patient characteristics.
Contraindications
- Carboplatin Medak is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds.
- It is also contraindicated in patients with severe bone marrow suppression, pre-existing kidney impairment, or bleeding disorders.
Side Effects
Common side effects of Carboplatin Medak may include myelosuppression, gastrointestinal disturbances, neurotoxicity, ototoxicity, and hypersensitivity reactions. Monitoring for adverse effects is essential during treatment.
Usage Instructions
Carboplatin Medak is administered via intravenous infusion over 15 to 60 minutes. The dosage is individualized based on the patient’s body surface area and renal function. It should not be mixed with aluminum-containing equipment due to potential drug precipitation.
Administration of Carboplatin Medak should be performed by healthcare professionals experienced in chemotherapy administration.
Benefits Compared to Analogues
Carboplatin Medak offers comparable efficacy to cisplatin with a lower incidence of nephrotoxicity and neurotoxicity. It has a more favorable safety profile in terms of gastrointestinal side effects compared to oxaliplatin.
Suitable Patient Groups
Carboplatin Medak can be used in various patient populations, including adults, elderly patients, and individuals with compromised renal function. Dose adjustments may be necessary in patients with renal impairment.
Storage and Shelf Life
Carboplatin Medak should be stored at controlled room temperature (20-25°C) and protected from light. The shelf life of the product is typically indicated on the packaging and should be checked before use.
Packaging Description
Carboplatin Medak is supplied in vials containing 10 mg/ml of the concentrated solution. Each vial is intended for single-use and should be visually inspected for particulate matter or discoloration before administration.
Clinical Evidence and Proven Effectiveness
Clinical studies have demonstrated the efficacy of Carboplatin Medak in the treatment of advanced ovarian carcinoma and other malignancies. The drug has shown significant antitumor activity and manageable toxicity profiles in various clinical trials.
